MedTrace Logo

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

NCT05263895 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-06-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to estimate the relative bioavailability of PF-07321332 in different formulations in healthy adult participants.

Conditions

  • Bioavailability

Interventions

DRUG

PF-07321332/ritonavir

PF-07321332 ritonavir will be administered as single dose orally

DRUG

PF-07321332/ritonavir

PF-07321332 ritonavir will be administered as single oral dose orally.

DRUG

PF-07321332/ritonavir

PF-07321332 ritonavir will be administered as single oral dose orally.

DRUG

PF-07321332/ritonavir

PF-07321332 ritonavir will be administered as single oral dose orally.

DRUG

PF-07321332

PF-07321332 will be administered as single oral dose orally.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-03
Primary Completion
2022-05-16
Completion
2022-05-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05263895 on ClinicalTrials.gov